# Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

> **NCT00651612** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 604 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
- **DRUG:** Concurrent brimonidine 0.2% and 0.5% timolol

## Key facts

- **NCT ID:** NCT00651612
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 604 (ACTUAL)
- **Last updated:** 2008-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651612, "Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00651612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*